Accurate Biotech Announces Close Of ￥100M Series A Financing Round

(VCBeat) Mar. 12, 2021 -- Recently, Accurate Biotechnology Co., Ltd. ("Accurate Biotech"), which focuses on the R&D and industrialization of organoids, announced the close of a Series A investment round worth nearly 100 million yuan, led by Funway Capital. Accurate Biotech plans to use the funds to promote the development, upgrading, and industrialization of products.

Headquartered in Guangzhou, Accurate Biotech is an innovative biomedical company with organoid-related technology as the core. It has subsidiaries including the Sino-European Institute for Organoid Research and a third-party medical laboratory. Accurate Biotech also owns an organoid R&D technology platform.

Accurate Biotech is committed to developing products in three directions, including individualized clinical treatment, new drug R&D and regenerative medicine, with a complete industry chain. The company has set up R&D centers in Beijing, Guangzhou, Shanghai, Macao, and Milan, Italy. Meanwhile, it has cooperated with more than 60 hospitals in China and set up laboratories in 10 core cities.

By providing comprehensive solutions in the fields of precision medicine, new drug development and basic research for cancer patients, Accurate Biotech is committed to building the whole industrial chain and technical standards of organoids. Accurate Biotech is one of the earliest enterprises in the field of organoids, and also the first company to obtain the patent of technology invention of organoids in China.

The excellent R&D, medical and operation management teams have laid a solid foundation for the development of Accurate Biotech. Under the leadership of Chief Scientist Professor Deng Chuxia, the R&D team of Accurate Biotech established a comprehensive organoid culture system and technical system and has carried out global strategic cooperation with multinational companies.

Funway Capital is a professional equity fund in the medical industry. The fund investors include a number of listed companies in the medical industry, government-oriented guidance funds, overseas investors, etc. It focuses on the fields of in vitro diagnosis, new drug R&D, CRO/CMO, and so on.